Life
Merck's HIV Prevention Pill: A Cost-Effective Solution Awaiting Generic Production
With estimates suggesting Merck's experimental HIV prevention pill could cost under $5 annually, researchers are calling for the company to allow generic production.
Editorial Staff
1 min read
Updated 10 days ago
Merck's experimental HIV prevention pill has been projected to cost less than $5 a year, according to recent research published by STAT.
Experts are urging Merck to take action by licensing the production of generic versions of the pill, which could enhance accessibility.
The implications of such a low-cost option could significantly impact at-risk populations, enhancing public health outcomes through improved accessibility.